Navigation Links
Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
Date:11/3/2011

and cash equivalents

$  71,074,807$
5,893,970Accounts receivable, net of allowances

4,505,4115,145,494Inventories

6,874,5997,683,842Other current assets

3,423,5742,315,536Total current assets

85,878,39181,038,842Property and equipment, net

1,198,8051,220,010Intangible assets, net

7,029,1867,427,223Other assets

1,972,2842,367,979Total assets

$  96,078,666$
92,054,054LIABILITIES AND EQUITYCurrent liabilities:Current portion of long-term debt

$
-$
2,666,668Accounts payable

3,280,2892,124,654Other current liabilities

4,172,9424,436,298Total current liabilities

7,453,2319,227,620Revolving line of credit

4,575,9511,825,951Long-term debt, excluding current portion

-2,666,665Other long-term obligations, excluding current portion

592,427618,343Total liabilities

12,621,60914,338,579Commitments and contingenciesEquity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;20,215,910 and 20,338,461 shares issued and outstandingas of September 30, 2011 and December 31, 2010, respectively

71,802,06870,778,874Retained earnings

11,744,9976,998,806Total shareholders' equity

83,547,06577,777,680Noncontrolling interests

(90,008)(62,205)Total equity

83,457,05777,715,475Total liabilities and equity

$  96,078,666$
92,054,054CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Income(Unaudited)Three months ended September 30,Nine months ended September 30,2011201020112010Net revenues

$
3,054,278$
2,190,870$
38,110,946$
33,061,457Costs and expenses:Cost of products sold

1,341,256909,4343,411,3542,632,447Selling and marketing

5,060,5465,692,04816,253,57417,147,683Research and development

1,233,0251,138,9553,269,7462,947,623General and administrative

2,117,6841,806,9756,442,1395,471,012Amortization of
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Cumberland Pharmaceuticals Taps Industry Veteran for Key Executive Position
2. Neurotech Announces the Opening of Its GMP Manufacturing Facility in Cumberland, Rhode Island
3. Cumberland Pharmaceuticals Appoints Lee Product Director
4. Cumberland Emerging Technologies and UT Research Foundation Sign License Agreement for New Technology
5. Cumberland Pharmaceuticals Provides Hospital In-Service Webcast for Acetadote(R)
6. Cumberland Pharmaceuticals Announces FDA Approval of Caldolor(TM)
7. Cumberland Pharmaceuticals Announces Pricing of Its Initial Public Offering of Common Stock
8. Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
10. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
11. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... January 14, 2014 iLab Solutions, the leader ... the new Director of Product Strategy. In this role, Michelle ... iLab sub-teams to guide in the development of iLab products. ... the maximum possible benefit to the scientific community by offering ...
(Date:1/14/2014)... 14, 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a ... innovative therapies addressing major unmet medical needs using ... Notice of Allowance from the United States Patent ... compounds (sd-rxRNA®), for the treatment of fibrosis. The ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... 14, 2014 Kerr Corporation, a leading manufacturer ... additional how-to information about dual arch impressions on its dental ... Arch Impressions,” the blog entry serves up a list of ... a step-by-step demonstration by Dr. David Little as he crafts ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... 1 Iomai Corporation,(Nasdaq: IOMI ) ... merger of,Iomai with a wholly-owned subsidiary of ... shares entitled to vote at the special,meeting ... of the,votes cast. The transaction remains subject ...
... MS, EDMONTON, Aug. 1 /PRNewswire-FirstCall/ - BioMS ... treatment of multiple sclerosis (MS), today,announced that it ... trial of MBP8298 (dirucotide) for the treatment of ... approximately,510 patients, and is being conducted at 68 ...
... Associates has announced the development of the Core Communications Program, ... investors, collaborators, and customers. , ... ... http://www.mainsgate.com [Mains Associates] has announced the availability of ...
Cached Biology Technology:BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial 2BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial 3BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial 4Bay-Area Company Gives Science-Based Startups a Voice 2
(Date:7/9/2014)... the bladders of healthy women differ from bacteria ... according to researchers from Loyola University Chicago Stritch ... July 9, 2014, in the American Society for ... bacterial communities may play a role in female ... a common, yet poorly understood, condition with symptoms ...
(Date:7/9/2014)... associate professor of plant pathology and microbiology ... the 2014 Alexopoulos Prize by the Mycological ... the science of mycology the study of fungi ... plant pathogens, and medically important fungi. , The award ... mycologist. Stajich received the award last month in East ...
(Date:7/9/2014)... As climate change shifts the geographic ranges in which ... it has on their parasites. Does an increased range ... as well? , Not necessarily, says a team of ... Armand Kuris. In a study published in the ... that for some species, the opposite may happen: Hosts ...
Breaking Biology News(10 mins):UC Riverside plant pathologist receives national recognition 2Not at home on the range 2Not at home on the range 3Not at home on the range 4
... COLUMBUS, Ohio Ohio State University cancer researchers ... brain-tumor cells and blocks the growth of new tumor ... to kill cancer cells oncolytic viruses might ... also carry a gene for a protein that inhibits ...
... NEW YORK, Dec. 1 iQor, a global provider of business ... 100 Awards Top 100 IT project of 2009 for its ... , "We are honored to be recognized among this prestigious list ... is completely transforming the way we do business, allowing us to ...
... bad cold, can spread among groups of people, research ... Diego and Harvard shows. Using longitudinal data from a ... more than 60 years, a team of scholars found ... others. Gradually over time, a group of lonely, disconnected ...
Cached Biology News:Tumor-attacking virus strikes with 'one-two punch' 2iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Loneliness can be contagious 2Loneliness can be contagious 3
... 26] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
One-step, microplate or cuvet, colorimetric, linear detection range 0.9 mg/dL to 200 mg/dL. Procedure: 2 min....
[5,6,8,9,12,14,15(n)-3H]Prostaglandin D2, 925 kBq, 25 uCi. Methanol:water:acetonitrile (3:2:1) solution.> 3.0 TBq/mmol, > 80 Ci/mmol.3.7 MBq/ml, 100 uCi/ml. Category: Radiochemicals &Radiation Safety...
Biology Products: